New shot aims to stop dangerous sugar crashes after gastric bypass
NCT ID NCT07029412
First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests a new drug called MBX 1416 in 10 people who have low blood sugar episodes after weight loss surgery. Participants receive two injections of the drug, a low dose and a high dose, about two weeks apart. The goal is to see if the drug can raise the lowest blood sugar level during a standard meal test, which could help control this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MBX 1416 (imapextide)
- What this could lead to
- If this works, it could point toward a new treatment to prevent dangerous blood sugar drops after weight loss surgery, improving daily life and safety.
- What could go wrong
- This is a very small, early-phase study with only 10 participants, so results may not apply to everyone. The drug is given only twice, and its long-term safety and effectiveness are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTBARIATRIC HYPOGLYCEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MBX Biosciences Investigational Site
Aurora, Colorado, 80045, United States
-
MBX Biosciences Investigational Site
Morehead City, North Carolina, 28557, United States
-
MBX Biosciences Investigational Site
Knoxville, Tennessee, 37920, United States
-
MBX Biosciences Investigational Site
San Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.